200 related articles for article (PubMed ID: 21763564)
1. Isotretinoin and iPledge: a view of results.
Maloney ME; Stone SP
J Am Acad Dermatol; 2011 Aug; 65(2):418-419. PubMed ID: 21763564
[No Abstract] [Full Text] [Related]
2. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity.
De Santis M; Straface G; Cavaliere A; Nobili E; Caruso A
Prev Med; 2007; 45(2-3):243-4. PubMed ID: 17640721
[No Abstract] [Full Text] [Related]
3. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
4. A pox on your practice. iPLEDGE program scars dermatologists.
Ortolon K
Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
[No Abstract] [Full Text] [Related]
5. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
Honein MA; Lindstrom JA; Kweder SL
Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
[TBL] [Abstract][Full Text] [Related]
6. [30 years with isotretinoin. "Miracle medicine" against acne with many side effects].
Mobacken H; Sundström A; Vahlquist A
Lakartidningen; 2014 Jan 15-28; 111(3-4):93-6. PubMed ID: 24552013
[No Abstract] [Full Text] [Related]
7. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
8. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
9. Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
Eur J Clin Pharmacol; 2013 Apr; 69(4):1041-2. PubMed ID: 23052415
[No Abstract] [Full Text] [Related]
10. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
11. An opportunity for improvement: iPLEDGE policy changes during the coronavirus pandemic.
Pathoulas JT; Farah RS; Fiessinger L; Mansh M
Dermatol Ther; 2020 Nov; 33(6):e14411. PubMed ID: 33052629
[No Abstract] [Full Text] [Related]
12. Does the teratogenicity of isotretinoin outweigh its benefits?
Jordan AY; Parks L; Chen SC; Higgins K; Fleischer AB; Feldman SR
J Dermatolog Treat; 2005; 16(4):190-2. PubMed ID: 16249139
[No Abstract] [Full Text] [Related]
13. Oral isotretinoin and pregnancy prevention programmes.
Thiboutot D; Gollnick H; Bettoli V; Dréno B; Kang S; Leyden JJ; Shalita A; Torres V;
Br J Dermatol; 2012 Feb; 166(2):466-7; author reply 467-8. PubMed ID: 21985025
[No Abstract] [Full Text] [Related]
14. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010.
Goodfield MJ; Cox NH; Bowser A; McMillan JC; Millard LG; Simpson NB; Ormerod AD
Br J Dermatol; 2010 Jun; 162(6):1172-9. PubMed ID: 21250961
[No Abstract] [Full Text] [Related]
15. [Pregnancy after isotretinoin use].
Manders KC; de Vries LC; Roumen FJ
Ned Tijdschr Geneeskd; 2013; 157(41):A6567. PubMed ID: 24103139
[TBL] [Abstract][Full Text] [Related]
16. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
17. FDA approves mandatory risk management program for isotretinoin.
Cuzzell JZ
Dermatol Nurs; 2005 Oct; 17(5):383. PubMed ID: 16294949
[No Abstract] [Full Text] [Related]
18. Accutane registry compulsory in US, but not Canada.
Andresen M
CMAJ; 2006 Jun; 174(12):1701. PubMed ID: 16754892
[No Abstract] [Full Text] [Related]
19. Circumventing iPLEDGE: Circumventing ethical responsibility?
Lee KC; Bercovitch L
J Am Acad Dermatol; 2017 Dec; 77(6):1185-1187. PubMed ID: 29132856
[No Abstract] [Full Text] [Related]
20. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
